OptiBiotix Signs Major Supply Agreement for its Microbiome Modulating Cholesterol-Reduction Probiotic

d6d4fdd0-bcf5-4480-8f73-4ee148db27dbarticleimage.jpg

19 Jun 2017 --- Life sciences company OptiBiotix has signed a three-year supply agreement with HLH BioPharma Vertriebs GmbH for its cholesterol-reducing LPLDL probiotic supplement. Research into the LPLDL probiotic, presented at Vitafoods Europe in May 2017, demonstrated that it is a safe natural ingredient which reduces blood pressure and cholesterol, key determinates of cardiovascular risk. 

According to the company, the probiotic was found to reduce LDL cholesterol by up to 13.9%, and blood pressure by 5.1%. This research was carried out by Glenn Gibson, Professor of Food Microbiology, Head of Food Microbial Sciences at University of Reading.

Stephen O’Hara, CEO of OptiBiotix, comments, “The development of our LPLDL probiotic product has made cholesterol reduction through microbiome modulation a reality, and we are thrilled to be working with HLH, one of Europe’s leading suppliers to the pharmacy market, on this product. The ability to create designer active ingredients which can modify an individual’s microbiome to improve health places OptiBiotix at the forefront of global microbiome research and product development, and we anticipate many more opportunities for the LPLDL probiotic.”

Microbiome modulators in the form of probiotic supplements, like LPLDL, may be the way forward for managing long-term conditions like cardiovascular disease (CVD). The reduction of both LDL cholesterol and blood pressure is key for managing the risk of CVD. The combination of high blood pressure and cholesterol deposition may lead to the chronic inflammation and hardening of the walls of the blood vessels, which greatly increases the probability of suffering a cardiovascular event. Recent research, presented at the European Society of Cardiology Congress 2016, demonstrated that reducing LDL cholesterol and blood pressure can reduce the lifetime risk of cardiovascular disease by nearly 90%.

The supply agreement grants HLH a non-exclusive license to produce, package, and commercialize products containing the LPLDL strain, and follows HLH’s recent order for 100,000 units of LPLDL. HLH has over 20 years’ experience in the distribution of probiotic and natural products under the brand names Lactobact and Casa Sana and is one of Europe’s leading suppliers of probiotics to the pharmacy market. LPLDL will be supplied as bulk capsules which will be packaged and branded as part of HLH’s market leading Lactobact brand.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Nutrition & Health News

Gluten-free mainstreams: Is the trend leading to unhealthy weight control?

18 Jun 2018 --- Individuals who value gluten-free foods are more likely to eat a higher quality diet but are also more likely to have unhealthy weight control behaviors. This is according to a new study exploring the sociodemographic and behavioral characteristics of young adults who value gluten-free as an important food claim.

Nutrition & Health News

Herza Schokolade seeks to combine protein with enjoyment with new chocolate range

18 Jun 2018 --- Herza Schokolade, a supplier of functional chocolate for further industrial processing, has launched a new range of high-protein chocolate and compound pieces for products such as cereals and bars.

Nutrition & Health News

Low maternal selenium may have consequences for mother's heart health in later life: Cypress Systems

18 Jun 2018 --- By increasing their risk of preeclampsia, mothers with low selenium levels may also be at increased risk for heart disease, stroke and high blood pressure later in life, a Cypress Systems executive summary suggests. The summary calls for higher levels of supplementation of high selenium yeast to combat heart health threats.

Nutrition & Health News

First time finding: Allergy to red meat may be a factor in heart disease

18 Jun 2018 --- A team of researchers says it has linked sensitivity to an allergen in red meat to the buildup of plaque in the arteries of the heart. While high saturated fat levels in red meat have long been known to contribute to heart disease for people in general, the new finding suggests that a subgroup of the population may be at heightened risk for a different reason – a food allergen. The study, which is supported by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health and appears in Arteriosclerosis, Thrombosis, and Vascular Biology.

Nutrition & Health News

DSM’s Nutrition Improvement focus: Fresh thinking on global nutrition and food fortification

15 Jun 2018 --- “We work with our customers and the larger malnutrition-fighting community to treat and prevent malnutrition,” Anthony Hehir, Director of DSM’s Nutrition Improvement Business Segment, tells NutritionInsight. Using its solid science and technical heritage, DSM is striving to fight global malnutrition through its “business with a purpose” approach. NutritionInsight spoke to Hehir, gaining an insight into what drives the company’s staple food fortification technologies, research and future nutrition endeavors. 

More Articles
URL : http://www.nutritioninsight.com:80/news/optibiotix-signs-major-supply-agreement-for-its-microbiome-modulating-cholesterol-reduction-probiotic.html